Nemaura Medical Inc. announced initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the United Kingdom. The initial pilot program recruited 30 individuals that were classified as obese according to their BMI. The first cohort of 10 patients have been enrolled in the program for over 12 weeks.

Results from this cohort indicate that these individuals achieved an average weight loss of 3.7 pounds and an average BMI improvement of 0.6 after 10 weeks, with 100% of participants achieving some weight improvement. This level of average weight loss exceeds some of the publicly reported results in studies of other weight loss programs. As the Miboko program is optimized, average weight loss is expected to increase. The program is designed to continue for at least one year, with new patients being enrolled each month.

Feedback from participants shows that use of the body-worn sensor led to greater engagement and an element of gamification that is anticipated to lead to sustained use and encourage incremental dietary and lifestyle changes through a combination of personalized data and targeted education modules. Participants expressed their willingness to continue with the program, reporting that they do not see Miboko as a traditional diet plan, which the Company expects will avoid diet fatigue and drop-off rates widely associated with many of the current weight loss programs. The Miboko program is the first to integrate a daily-wear non-invasive glucose sensor with a lifestyle app, which includes recording of food and drink, educational content, and an analytics platform. The wellness program provides each user a metabolic score based on diet, exercise, and glucose response to food intake, which is determined by the sensor.

Users are given personalized recommendations to help them lose weight, potentially avoid chronic health issues, and enjoy a better quality of life. As studies continue, lessons learned will be used to improve and introduce new features into the program. The integration of Nemaura's daily-wear non-invasive glucose sensor is a unique feature that is unavailable in any other plan, and the Company is now evaluating options to provide the core part of the program and glucose sensors as add-ons to existing diet and metabolic health programs globally.

The Company expects the UK National Health Service will publish detailed study results following further analysis.